Diana O. Perkins
YOU?
Author Swipe
View article: Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics
Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics Open
Historically, large samples of individuals at clinical high risk (CHR) for psychosis have mirrored overt psychotic disorders in both sex (predominantly male) and age representation (adolescent to early adulthood onset). We report on a rece…
View article: Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts
Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts Open
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (co-use) is rising in the general population but has not bee…
View article: Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms
Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms Open
Background Reduced mismatch negativity (MMN) and P300 event-related potential (ERP) components are widely replicated in schizophrenia and are also observed in individuals at clinical high risk for psychosis (CHR-P) who subsequently convert…
View article: Predictors and Moderators of Long-Term Outcome of Persons at Clinical High Risk for Psychosis: Methods and Preliminary Data
Predictors and Moderators of Long-Term Outcome of Persons at Clinical High Risk for Psychosis: Methods and Preliminary Data Open
Background and Hypothesis Despite significant advances in our understanding of the clinical high risk (CHR) for psychosis state, the longer-term outcomes (5+ years) and the trajectory of diagnoses, symptoms, and psychosocial function have …
View article: Altered brain activation during memory retrieval mediates the relationship between developmental trauma and psychotic symptom severity
Altered brain activation during memory retrieval mediates the relationship between developmental trauma and psychotic symptom severity Open
These findings suggest a role of episodic memory processing and inferior parietal lobe activation in the association between DT and psychosis. Focusing further on these measures could provide insight into the underlying mechanism of this a…
View article: Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Open
Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Me…
View article: Association of Childhood Area-Level Ethnic Density and Psychosis Risk Among Ethnoracial Minoritized Individuals in the US
Association of Childhood Area-Level Ethnic Density and Psychosis Risk Among Ethnoracial Minoritized Individuals in the US Open
Importance: The protective ethnic density effect hypothesis, which suggests that minoritized individuals who grow up in neighborhoods with a high proportion of ethnoracial minoritized groups are protected from the effects of perceived disc…
View article: Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption
Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption Open
The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies compl…
View article: Delineating empirically plausible causal pathways to suicidality among people at clinical high risk for psychosis.
Delineating empirically plausible causal pathways to suicidality among people at clinical high risk for psychosis. Open
Suicidality is common among people at clinical high risk (CHR) for psychosis. Delineating causal pathways to suicidality and identifying its determinants would inform tailored intervention efforts for these individuals. To this end, we ana…
View article: Predicting conversion to psychosis using machine learning: response to Cannon
Predicting conversion to psychosis using machine learning: response to Cannon Open
Background We previously reported that machine learning could be used to predict conversion to psychosis in individuals at clinical high risk (CHR) for psychosis with up to 90% accuracy using the North American Prodrome Longitudinal Study-…
View article: Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis
Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis Open
Background Antipsychotic (AP) medication in individuals at clinical high risk for psychosis (CHR-P) is not routinely recommended by clinical guidelines but is commonly prescribed. Since little is known about the predictors of AP inception …
View article: Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical …
View article: Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and …
View article: Mismatch Negativity as an Index of Auditory Short-Term Plasticity: Associations with Cortisol, Inflammation, and Gray Matter Volume in Youth at Clinical High Risk for Psychosis.
Mismatch Negativity as an Index of Auditory Short-Term Plasticity: Associations with Cortisol, Inflammation, and Gray Matter Volume in Youth at Clinical High Risk for Psychosis. Open
Mismatch negativity (MMN) event-related potential (ERP) component reduction, indexing N-methyl-D-aspartate receptor (NMDAR)-dependent auditory echoic memory and short-term plasticity, is a well-established biomarker of schizophrenia that i…
View article: Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis
Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis Open
Attention Deficit Hyperactivity Disorder (ADHD) affects a significant proportion of the population and is associated with numerous adverse outcomes including lower educational attainment, occupational challenges, increased substance use, a…
View article: Protective Factors Predict Resilient Outcomes in Clinical High-Risk Youth with the Highest Individualized Psychosis Risk Scores
Protective Factors Predict Resilient Outcomes in Clinical High-Risk Youth with the Highest Individualized Psychosis Risk Scores Open
Background and Hypothesis Studying individuals at Clinical High Risk (CHR) for psychosis provides an opportunity to examine protective factors that predict resilient outcomes. Here, we present a model for the study of protective factors in…
View article: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis Open
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories a…